Business Context and Reporting Period
This unaudited Form 10-Q covers the nine months and three months ended September 30, 2019. The source filing identifies the registrant as Seneca Biopharma, Inc., formerly Neuralstem, Inc.; it does not identify Palisade Bio, Inc. The company is a clinical-stage biopharmaceutical developer focused on NSI-566 neural stem-cell therapy, NSI-189 small-molecule programs, and potential acquired or in-licensed technologies. The company changed its name to Seneca Biopharma in October 2019.
Key Financial Metrics
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $2,500 | $2,500 | $12,894 | $257,500 |
| Operating expenses | $2.13 million | $2.09 million | $6.51 million | $6.71 million |
| Operating loss | $(2.12) million | $(2.08) million | $(6.50) million | $(6.45) million |
| Net loss | $(1.76) million | $(1.83) million | $(6.31) million | $(4.60) million |
| Net loss per share | $(0.59) | $(2.41) | $(4.80) | $(6.08) |
| Cash used in operations | Not separately provided | Not separately provided | $(5.21) million | $(6.03) million |
Revenue consisted primarily of intellectual-property license fees; the company generated no product sales. Gross margin is not meaningful because revenue was minimal and the filing does not present a conventional gross-margin measure. Other income was $361,000 in the third quarter and $185,000 for the first nine months, including non-cash warrant fair-value gains of $321,000 and $417,000, respectively.
At September 30, 2019, cash and cash equivalents were $7.30 million, total assets were $8.94 million, current liabilities were $1.58 million, total liabilities were $1.90 million, and stockholders’ equity was $7.04 million. Short-term notes and other current liabilities were $400,016; the filing does not provide a conventional long-term debt balance. The company reported an accumulated deficit of $219.94 million.
Material Changes Versus the Prior Comparable Period
- Nine-month revenue declined by $244,606, primarily because the prior-year period included a $250,000 milestone-related royalty from a patent settlement; recurring license fees were $7,500 in each period.
- Third-quarter operating expenses increased 2% to $2.13 million. Research and development expense decreased 8%, while general and administrative expense increased 10%, partly because of higher non-cash share-based compensation.
- Nine-month operating expenses decreased 3% overall. Research and development expense increased 7%, mainly from consulting costs related to strategic alternatives, while general and administrative expense decreased 11% due to cost-cutting efforts.
- Nine-month net loss increased by $1.71 million, largely because the prior-year period benefited from a $1.81 million non-cash warrant fair-value gain, compared with a $417,000 gain in 2019, and because of a $368,000 write-off of a related-party receivable in 2019.
- Operating cash burn improved by $828,000 year over year, while financing cash flow increased by $6.62 million due primarily to the July 2019 equity and warrant offering.
- The company completed a 1-for-20 reverse stock split in July 2019 and raised approximately $6.6 million of net proceeds through an underwritten offering. The offering included substantial warrants and resulted in significant potential dilution.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects existing cash to fund the current operating plan into the third quarter of 2020, but states that substantial doubt remains about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Additional capital will be required for clinical and preclinical development, operations, and any acquisition or in-licensing activities. The company has no committed future funding and may seek equity or debt financing, grants, licensing transactions, or collaborations.
- On October 31, 2019, the company announced a non-binding term sheet with Jiangsu QYuns Therapeutics for an exclusive license to cytokine-targeted monoclonal antibody assets. The transaction remained subject to definitive agreements, shareholder approval, other conditions, and issuance of an undetermined number of equity securities.
- The company expects continued operating losses and does not expect profitability in the next several years. Its clinical programs remain subject to clinical, regulatory, manufacturing, intellectual-property, reimbursement, and third-party execution risks.
- The NSI-566 exploratory Phase 2 ischemic-stroke trial had completed enrollment, with clinical results anticipated in the second half of 2020. The company stated that the study results were not expected to support a regulatory submission.
- The company recorded a full allowance against the remaining $229,000 related-party receivable after forgiving approximately 50% of the original balance under a separation and consulting arrangement.
- As of September 30, 2019, approximately 8.0 million warrants were outstanding, in addition to options, restricted stock units, preferred-stock conversion rights, and other equity awards. These instruments create substantial potential dilution.
- Management reported that disclosure controls and procedures were effective as of September 30, 2019, with no material changes in internal control over financial reporting during the quarter. No legal proceedings were reported.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Seneca Biopharma, formerly Neuralstem, not Palisade Bio.
- Verify the company’s ability to raise additional capital before the projected cash runway ends in the third quarter of 2020.
- Review the July 2019 offering, warrant terms, anti-dilution provisions, and the resulting fully diluted share count.
- Assess whether the QYuns licensing transaction progressed beyond its non-binding term sheet and determine the expected equity consideration.
- Evaluate the status, funding, and future regulatory usefulness of the NSI-566 and NSI-189 programs.
- Reconcile the reported cash balance, operating cash burn, debt obligations, lease liabilities, and going-concern disclosure.
- Review subsequent filings for the company-name change, clinical updates, financing activity, Nasdaq listing compliance, and any changes to the going-concern assessment.